Edition:
United Kingdom

Ambu A/S (AMBUb.CO)

AMBUb.CO on Copenhagen Stock Exchange

90.08DKK
2:19pm BST
Change (% chg)

kr.-2.40 (-2.60%)
Prev Close
kr.92.48
Open
kr.90.00
Day's High
kr.91.00
Day's Low
kr.87.86
Volume
1,458,178
Avg. Vol
1,472,259
52-wk High
kr.279.60
52-wk Low
kr.85.30

Latest Key Developments (Source: Significant Developments)

Ambu A/S Is Expanding Its Product Portfolio And Commercial Infrastructure
Monday, 17 Jun 2019 

June 17 (Reuters) - Ambu A/S ::IS EXPANDING ITS PRODUCT PORTFOLIO AND COMMERCIAL INFRASTRUCTURE.FINANCIAL OUTLOOK ADJUSTED TO REFLECT COMMERCIAL INVESTMENTS AND NEW PRODUCT LAUNCH TIMELINES.LAUNCH OF CYSTOSCOPE INTO UROLOGY MARKET IS EXPECTED TO COME EARLIER THAN EXPECTED.TOTAL INCREMENTAL COST IS ESTIMATED TO BE DKK 225M IN 2019/20.EXPANSION WILL MORE THAN DOUBLE CO'S GLOBAL VISUALIZATION SALESFORCE.HIRING WILL START IN Q4 2018/19 WITH AN ESTIMATED COST IN 2018/19 OF APPROX. DKK 20M.SEES EBIT-MARGIN BEFORE SPECIAL ITEMS OF APPROX. 22% COMPARED TO PREVIOUSLY STATED 22-24% FOR CURRENT FISCAL YEAR 2018/19.SEES FOR CURRENT FY ORGANIC GROWTH OF APPROX. 14-15% COMPARED TO PREVIOUSLY STATED 15-16%.SEES FREE CASH FLOWS OF APPROX. DKK 375M COMPARED TO PREVIOUSLY STATED DKK 400-475M FOR CURRENT FISCAL YEAR 2018/19.REASON FOR ADJUSTMENT OF GROWTH IS DUE TO DISCONTINUATION OF SC210.ADJUSTMENT OF EBIT MARGIN IS DRIVEN BY LOWER GROWTH AND INVESTMENTS IN COMMERCIAL INFRASTRUCTURE.EXPECTATION IS TO SELL APPROX. 1.000.000 ENDOSCOPES UNITS IN 2019/20 COMPARED TO PREVIOUSLY STATED +1,000,000.ORGANIC GROWTH IN 2019/20 IS ESTIMATED IN RANGE OF 16-19% COMPARED TO PREVIOUSLY 18-23.SPECIAL ITEMS RELATED TO REPLACEMENT OF AMBU'S CEO ARE UNCHANGED AND EXPECTED TO BE DKK 38M.  Full Article

Cook Medical, Ambu Announce Collaboration To Address Endoscope-Related Infections
Saturday, 18 May 2019 

May 18 (Reuters) - Ambu A/S ::REG-AMBU A/S: COOK MEDICAL AND AMBU ANNOUNCE COLLABORATION TO ADDRESS ENDOSCOPE-RELATED INFECTIONS.COOK MEDICAL AND AMBU ANNOUNCE COLLABORATION TO ADDRESS ENDOSCOPE-RELATED INFECTIONS.COOK MEDICAL, CO HAVE AGREED ON TERMS TO ENTER INTO PARTNERSHIP IN WHICH COOK WILL DISTRIBUTE CO'S SINGLE-USE, DISPOSABLE DUODENOSCOPE IN U.S..NO FURTHER DETAILS ABOUT AGREEMENT WITH COOK MEDICAL WILL BE DISCLOSED AT THIS TIME.AGREEMENT IS NOT EXPECTED TO HAVE ANY IMPACT ON OUTLOOK FOR AMBU CONCERNING GROWTH, EARNINGS OR FREE CASH FLOWS TOWARDS SEPTEMBER 2020.AMBU IS CURRENTLY PURSUING REGULATORY CLEARANCE FROM U.S. FDA FOR ITS SINGLE-USE DUODENOSCOPE.  Full Article

Ambu Q1 2018/19 EBIT Rises To DKK 112 Million
Thursday, 31 Jan 2019 

Jan 31 (Reuters) - Ambu A/S ::REG-AMBU A/S: INTERIM REPORT FOR Q1 2018/19.REG-AMBU A/S: INTERIM REPORT FOR Q1 2018/19.IN Q1, AMBU REALISED ORGANIC GROWTH OF 15% AND A 43% INCREASE IN SALES OF ENDOSCOPES TO 149,000 UNITS..OUTLOOK FOR FINANCIAL YEAR ANNOUNCED IN ANNUAL REPORT FOR 2017/18 ON 13 NOVEMBER 2018 IS MAINTAINED.REVENUE OF DKK 656M (DKK 553M) WAS POSTED FOR Q1.Q1 2018/19 EBIT DKK 112 MILLION VERSUS DKK 91 MILLION YEAR AGO.SALES OF ENDOSCOPES IN Q1 REACHED 149,000 UNITS (104,000 UNITS), UP 43% RELATIVE TO Q1 LAST YEAR.."WE ARE SEEING AN INCREASING EFFECT OF APPROX. 50 EXTRA SALES REPRESENTATIVES HIRED IN USA OVER PAST YEAR".  Full Article

Ambu Q4 EBIT Increases to DKK 165 Mln
Tuesday, 13 Nov 2018 

Nov 13 (Reuters) - Ambu A/S ::REG-AMBU A/S: ANNUAL REPORT 2017/18 (EARNINGS RELEASE).REG-AMBU A/S: ANNUAL REPORT 2017/18 (EARNINGS RELEASE).Q4 2017/18 ORGANIC GROWTH OF 15% (14%) WAS REALISED IN Q4 IN LOCAL CURRENCIES, BASED ON REVENUE OF DKK 729M (DKK 629M).Q4 EBIT INCREASED TO DKK 165M (DKK 134M) WITH AN EBIT MARGIN OF 22.6% (21.3%). FY 2017/18.MANAGEMENT'S OUTLOOK FOR 2018/19 IS UNCHANGED RELATIVE TO MOST RECENTLY ANNOUNCED OUTLOOK ON 4 OCTOBER 2018.FY 2017/18 REVENUE FOR FINANCIAL YEAR WAS DKK 2,606M (DKK 2,355M) BASED ON ORGANIC GROWTH IN LOCAL CURRENCIES OF 15% (14%).PROPOSES THAT DIVIDEND OF DKK 0.40 (DKK 0.37) BE PAID PER SHARE.SAYS IS ON TRACK TO REALISING TARGETS OF ITS 2020 STRATEGY..  Full Article

Ambu Updates 2020 Strategy And Upgrades Financial Targets
Thursday, 4 Oct 2018 

Oct 4 (Reuters) - Ambu A/S ::REG-AMBU A/S: AMBU UPDATES 2020 STRATEGY AND UPGRADES FINANCIAL TARGETS IN CONNECTION WITH CAPITAL MARKETS DAY 2018.REG-AMBU A/S: AMBU UPDATES 2020 STRATEGY AND UPGRADES FINANCIAL TARGETS IN CONNECTION WITH CAPITAL MARKETS DAY 2018.TARGET REVENUE CAGR FOR THE THREE-YEAR PLAN TO BE INCREASED FROM “13-15%” TO “16-18%”,.TARGET EBIT MARGIN IN 2019/20 TO BE LIFTED FROM “24-25%” TO “26-28%”.TARGET FCF TO BE MAINTAINED AT “ AROUND 18% OF REVENUE IN 2019/20”.FOR THE FINANCIAL YEAR 2018/19, EXPECTS AN ORGANIC GROWTH RATE IN THE LEVEL OF 15-16%.FOR THE FINANCIAL YEAR 2018/19, EXPECTS EBIT-MARGIN IN THE INTERVAL 22-24%.OUTLOOK FOR THE FINANCIAL YEAR 2017/18 REMAINS UNCHANGED.  Full Article

Ambu: Chr. Augustinus Fabrikker Akts. Reduced Its Shareholding In Ambu To 4.9% Of Share Capital
Wednesday, 5 Sep 2018 

Sept 5 (Reuters) - Ambu A/S ::REG-AMBU A/S: MAJOR SHAREHOLDER ANNOUNCEMENT.CHR. AUGUSTINUS FABRIKKER AKTS. HAS SOLD 13,500,000 AMBU SHARES.AMBU - CHR. AUGUSTINUS FABRIKKER AKTS. REDUCED ITS SHAREHOLDING IN AMBU A/S TO 4.9% OF SHARE CAPITAL.  Full Article

Ambu Q2 2017/18 EBIT Rises To DKK 156 Million
Monday, 7 May 2018 

May 7 (Reuters) - AMBU A/S ::REG-AMBU A/S: INTERIM REPORT FOR Q2 2017/18 AND FOR THE HALF-YEAR (1 OCTOBER 2017- 31 MARCH 2018).REG-AMBU A/S: INTERIM REPORT FOR Q2 2017/18 AND FOR THE HALF-YEAR (1 OCTOBER 2017- 31 MARCH 2018).OUTLOOK FOR ORGANIC GROWTH IN LOCAL CURRENCIES FOR 2017/18 IS RAISED FROM 'APPROX. 13%' TO 'APPROX. 14-15%'.OUTLOOK FOR EBIT MARGIN AND FREE CASH FLOWS IS MAINTAINED..REVENUE OF DKK 651M WAS POSTED FOR Q2.Q2 2017/18 EBIT DKK 156 MILLION VERSUS DKK 121 MILLION YEAR AGO.  Full Article

Ambu: Completion Of Share Buyback Programme
Monday, 30 Apr 2018 

April 30 (Reuters) - AMBU A/S ::COMPLETION OF SHARE BUYBACK PROGRAMME (NO. 29).IN TOTAL, DURING THE SHARE BUYBACK PROGRAMME AMBU BOUGHT 3,850,000 SHARES.  Full Article

Ambu Reduces Nominal Value Of Each A And B Share​
Monday, 18 Dec 2017 

Dec 18 (Reuters) - Ambu A/S ::‍DECIDED TO REDUCE NOMINAL VALUE OF EACH A AND B SHARE FROM DKK 2.50 PER SHARE TO DKK 0.50 PER SHARE.​.- ‍EACH A- OR B-SHARE OF NOM. VALUE DKK 2.50 WILL THUS BE SPLIT IN FIVE NEW A- OR B-SHARES OF NOM VALUE DKK 0.50 PER SHARE​.  Full Article

Ambu Q4 2016/17 EBIT up at DKK ‍134​ million
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - AMBU A/S :Q4 2016/17 EBIT DKK ‍134​ MILLION VERSUS DKK 131 MILLION YEAR AGO.‍OUTLOOK FOR 2017/18 IS UNCHANGED RELATIVE TO MOST RECENTLY ANNOUNCED OUTLOOK ON 25 OCTOBER 2017​.AMBU A/S - ‍Q4 2016/17 ORGANIC GROWTH OF 14% (8%) WAS REALISED IN Q4 IN LOCAL CURRENCIES, BASED ON REVENUE OF DKK 629M (DKK 573M)​.  Full Article